Plus: dulaglutide vs. liraglutide; telephonic diabetes interventions
June 27, 2020 : Issue #1048 TOP STORIES - Diabetes News & Research |
|
Letter from the Editor
Although many of us would have liked to spend a week in Chicago at the ADA Scientific Sessions, the pandemic forced us to miss a chance to have some great food and fun. Although the live session is always good, it was kind of nice to do the sessions at your leisure via the web. One of the best parts was the opportunity to review things and share with others.
There was a study presented that looked at a once a week basal insulin. This grabbed me as a drug I wanted to learn more about, so I gave our intern, Lawand Kamal, PharmD Candidate 2021, Skaggs School of Pharmacy and Pharmaceutical Sciences, the project to teach me about this new insulin.
My thought process was that if this works, you give a patient one shot of insulin and a weekly GLP-1, and without a doubt you have the best 1-2 punch for managing type 2 diabetes. Check out what Lawand taught me by clicking here.
*****************************
We can make a difference!
*****************************
Dave Joffe
Editor-in-chief |
|
|
Doctor's Option lab test products include rapid tests and CLIA certified fingerstick lab tests.
Rapid tests offer immediate test results to provide doctors with point of care test results in as little as 90 seconds.
Fingerstick lab tests provide CLIA certified lab accurate results. Each fingerstick lab test collection kit comes with a prepaid postage return envelope and everything you need to obtain and collect your fingerstick blood sample in a 510K FDA approved device.
Fingerstick lab tests are great for people who want to monitor their blood sugar, cholesterol, lipids and other important bio-markers at home or on the go.
Visit Doctor's Option |
|
|
|
|
TOP STORIES - Diabetes News and Research |
|
| |
|
|
|
| Fact: Will Once Weekly Basal Insulin Hit or Miss?
New research suggests that the investigational once-weekly basal insulin analog icodec (Novo Nordisk) was comparable in efficacy and safety to once-daily insulin glargine U100. But will patients make the change? Julio Rosenstock, MD, of University of Texas Southwestern Medical Center at Medical City, Dallas, presented the data at the ADA's Scientific Sessions last week.
They found that insulin icodec has a 196-hour half-life. This insulin is designed to cover a person's basal insulin requirements for a full week with a steady insulin release. We know that most people with T2D are reluctant to start on insulin due to the need for daily injections. This was a phase 2 study, and we need to wait until phase 3 data is completed before making any final decisions. The primary endpoint, change in A1c from baseline to week 26, dropped 1.33 percentage points with icodec.
The difference between the two groups in moderate or clinically significant hypoglycemia wasn't statistically significant (P = .85), and the duration of hypoglycemia wasn't longer with icodec compared with glargine, despite its longer duration of action, Rosenstock explained.
If the data is confirmed in the phase 3 study, "I believe personally that weekly basal insulin has the potential to be transformational in the management of people with type 2 diabetes needing insulin therapy." See item #1
ADA 2020 Scientific Sessions. Presented June 14, 2020. Abstracts 236-OR, 237-OR, 238-OR. |
|
|
| Diabetes in Control gratefully acknowledges the assistance of the following pharmacy doctoral candidates in the preparation of this week’s newsletters: David Clarke, PharmD Candidate, University of Colorado, Skaggs School of Pharmacy and Pharmaceutical Sciences Kenya Henderson, 2021 PharmD. Candidate, Florida Agricultural & Mechanical University, College of Pharmacy and Pharmaceutical Sciences Lawand Kamal, PharmD Candidate 2021, Skaggs School of Pharmacy and Pharmaceutical Sciences Jacob Roberts, PharmD Candidate 2021 of University of Colorado Denver Skaggs School of Pharmacy and Pharmaceutical Sciences |
|
|
|
|
|
| | About LaterPay: You will notice that some of our articles are now marked with a small credit card icon. This means you will be asked to pay a small fee to access the full article text (the cost is $0.39 per article, and you will be charged only after you have reached $5.00 in article views). The costs of producing a newsletter like Diabetes in Control have been increasing, which is why we are asking our readers to help support our ability to continue to bring you quality information about diabetes through charging a minimal price to read certain articles. Thank you for helping to support Diabetes in Control. |
| Your Friends in Diabetes Care
Steve and Dave
Diabetes In Control
810 Bear Tavern Road Suite 102
Ewing, NJ, 08628
USA
www.diabetesincontrol.com |
|
|
|
|
| | |
|
|
|
|
